This study tests the safety and effectiveness of **lorundrostat**, a medicine added to **SGLT2 inhibitors**, for people with high blood pressure and kidney disease. SGLT2 inhibitors help lower blood sugar and blood pressure. The study is **double-blind**, meaning neither doctors nor participants know who gets lorundrostat or a fake pill (placebo). Participants will be adults with high blood pressure and mild to severe kidney disease. They need to be on steady medicine like ACE inhibitors or ARBs, which help relax blood vessels.

The study has four main parts: a 2-week screening to check if participants qualify, a 2-week period to confirm medicine use, two 4-week treatment periods where participants receive lorundrostat or placebo, and a 4-week break in between. Participants are randomly assigned to receive either lorundrostat then placebo or placebo then lorundrostat.

• Study length is about 12 weeks, plus 2 weeks for screening.
• Participants must be on stable ACEi or ARB treatment.
• People with allergies to study medicines or severe health conditions are excluded.